Immune Thrombocytopenic Purpura - Pipeline Insight, 2024

Immune Thrombocytopenic Purpura - Pipeline Insight, 2024

DelveInsight’s, “Immune Thrombocytopenic Purpura - Pipeline Insight, 2024,” report provides comprehensive insights about 30+ companies and 25+ pipeline drugs in Immune Thrombocytopenic Purpura pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Immune Thrombocytopenic Purpura Understanding

Immune Thrombocytopenic Purpura: Overview

Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune disorder, in which the patient have low levels of cells platelets, which helps in clotting of the blood. Symptoms associated with Immune Thrombocytopenic Purpura include low platelet count, excessive bruising, superficial bleeding into the skin, mucosal bleeding, blood in urine or stools, heavy menstrual flow in case of females. Early diagnoses of ITP is challenging as the patient might not exhibit any symptoms. The diagnosis of ITP is made by physical examination, medical history, and blood test to count the platelets. There are various types of treatments available for the treatment of Immune Thrombocytopenic Purpura. Medications include steroids, Immune globulins and drugs that are responsible for treating platelets. Surgery is also one of the options in order to treat Immune Thrombocytopenic Purpura if medication doesn’t work. The surgical procedure includes the removal of spleen in order to prevent the attack on platelets and improve platelet count.

""Immune Thrombocytopenic Purpura - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Immune Thrombocytopenic Purpura R&D. The therapies under development are focused on novel approaches to treat/improve Immune Thrombocytopenic Purpura.

Immune Thrombocytopenic Purpura Emerging Drugs Chapters

This segment of the Immune Thrombocytopenic Purpura report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immune Thrombocytopenic Purpura Emerging Drugs

• Rilzabrutinib: Sanofi

Rilzabrutinib is a reversible, covalent inhibitor of Bruton’s tyrosine kinase is usually used to increase the platelet count in patients suffering from Immune Thrombocytopenic Purpura. The drug blocks the inflammatory immune cells, eliminate autoantibody destructive signaling, and helps to prevent new autoantibody production without depleting B cells. The drug is administrated orally and is being developed by Sanofi. In November 2020, FDA granted Rilzabrutinib Fast track designation for the treatment of Immune Thrombocytopenic Purpura. The drug right now is being investigated for the in phase III clinical trial for the treatment of Immune Thrombocytopenic Purpura.

• Mezagitamab: Takeda

Mezagitamab is also known as TAK-079, is a fully human, IgG1 monoclonal antibody, which is responsible for targeting CD38. CD38 is a cell surface molecule that is highly expressed on myeloma cells, plasma cells, plasmablasts, and natural killer (NK) cells, and is induced on activated T cells and other suppressor cells including regulatory T (Tregs) and B (Bregs) cells. The drug is being developed by Takeda and right now it is in Phase II clinical studies for the treatment of immune thrombocytopenic purpura.

Further product details are provided in the report……..

Immune Thrombocytopenic Purpura: Therapeutic Assessment

This segment of the report provides insights about the different Immune Thrombocytopenic Purpura drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Immune Thrombocytopenic Purpura

There are approx. 30+ key companies which are developing the therapies for Immune Thrombocytopenic Purpura. The companies which have their Immune Thrombocytopenic Purpura drug candidates in the most advanced stage, i.e. phase III include, Sanofi

• Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Immune Thrombocytopenic Purpura pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immune Thrombocytopenic Purpura: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpura therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpura drugs.

Immune Thrombocytopenic Purpura Report Insights

• Immune Thrombocytopenic Purpura Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Immune Thrombocytopenic Purpura Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Immune Thrombocytopenic Purpura drugs?
• How many Immune Thrombocytopenic Purpura drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenic Purpura?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenic Purpura therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Immune Thrombocytopenic Purpura and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanofi
• Takeda
• Rigel Pharmaceuticals
• Bristol-Myers Squibb

Key Products

• rilzabrutinib
• Mezagitamab
• Rozanolixizumab
• BMS-986004